

VOLUME 73, 2002 KEYWORD INDEX

- Abstinence, 491
Accuracy, 829
Acetylcholine, 679
Acetylcholinesterase, 893
AChacetylcholine, 511
Achievement tests, 491
(1S,3R)-ACPD, 439
ACTH, 209
Activity, 45
AD, 511
Addiction, 835
Adenosine, 573
Adenosine kinase, 573
Adjunctive behavior, 27
Adolescence, 713
Adolescent, 673
 α -Adrenoceptors, 941
 α_1 -Adrenoceptor agonist, 971
Affective state, 259
Affiliation, 61, 769
Ageing, 797
Age-related deficits, 233
Aggression, 7, 713, 769
Aging, 689, 863
Agonist, 545
AIDA, 439
Akinesia, 455
Alcohol, 491
Alcohol craving, 27
Alcohol-preference, 697
Allodynia, 401
Allopregnanolone, 77
Alternation, 723
Alternative reinforcer, 663
Alzheimer's disease, 565
Aminochrome, 843
4-Aminopyridine, 921
Amperozide, 769
Amphetamine, 333, 347
D-Amphetamine, 729
Amygdala, 147
Amyotrophic lateral sclerosis, 447
Anabolic–androgenic steroids, 713
Analgesia, 521, 573, 821, 863
Androgenic effects of levonorgestrel, 951
Animal cognition, 279
Animal model, 631
Antagonist, 611
Antidepressant, 147
Antidepressants, 247, 703
Antioxidant, 647
Antioxidants, 623, 797
Antisense oligonucleotide, 401
Anxiety, 209, 233, 359, 703, 851, 963
Anxiolytic, 359
Anxiolytics, 703
Ascorbic acid, 623
Ataxia, 673
Atypical antipsychotic, 769
Auditory startle response, 131
Bacopa monniera, 893
Balance, 673
Basal forebrain, 511
BD 1047, 779
Bed nucleus of the stria terminalis, 147
Behavior, 105, 159, 209, 247, 271, 877
Behavioral arousal, 259
Behavioral enrichment, 279
Behavioral syndrome, 647
BHK; baby hamster kidney, 439
“Binge” cocaine, 655
Biperiden, 829
Body temperature, 779, 805
Brain-derived neurotrophic factor, 167, 317
Brain electrical stimulation, 27
Brown adipose tissue (BAT), 639
Buspirone, 359
C57BL/6J mice, 655
Caffeine, 631
Calcium channel, 631
Cannabinoid agonist, 911
Cannabinoid antagonist, 911
Cannabis, 835
CB₁ receptor, 835
CBPG, 439
L-CCG-I, 347
CDP, 759
CEI; cholinesterase inhibitor, 511
Cell-mediated immune responses, 271
Channelopathy, 631
ChAT, 511
Cholecystokinin, 593
CHPG, 439
Chronic constriction injury, 411
Chronic sucrose feeding, 601
Chronic treatment, 877
Chronic treatments, 557
Circadian rhythm, 805
Clozapine, 769, 929
Cocaine, 663, 697, 769, 787, 877
Cocaine self-administration, 813
Cognition, 491, 893
Cognitive learning set, 723
Colchicine, 565
Conditioned place aversion, 941
Conditioned place preference, 655, 941
Conditioned taste aversion, 787
Conditioning, 611
Conflict, 359
Contraceptive progestins, 951
Cortical neurons, 287
Cortical slices, 327
Corticosteroid receptor, 147
Corticosterone, 7, 77, 95, 141, 193, 209, 689, 971
Corticotropin-releasing hormone, 147
Cortisol response, 259
CPCCOEt, 439
Cross-sensitization, 835
D1 receptor, 7
D₂ antagonist, 505
D₃ receptors, 753
Defense, 769

- Delta, 611
 Dementia, 511, 893
 Descending inhibition, 429
 Desensitization, 299
 Development, 61, 141, 447, 713
 Dexamethasone, 971
 DHPG, 347
 3,5-DHPG, 439
 Diazepam, 359
 Diet preference, 529
 DIV, 439
 DOI, 537
 DOI ((±)1-(2,5-dimethoxy-4-iodo-phenyl)-2-aminopropane), 327
 Donepezil, 511
 Donepezil (Aricept), 511
 Dopachrome, 843
 Dopamine, 7, 347, 679, 729, 843
 Dopamine antagonist, 869
 Dose–response, 901
 Drug abuse, 835
 Drug discrimination, 753, 759
 Drug use, 491
 DTG, 779
- Early deprivation, 259
 Early experience, 233
 Early handling, 87
 Early weaning, 45
 EEG, 467
 Electroconvulsive treatment, 159
 Elevated plus-maze, 123, 963
 Elevated plus-maze test, 131
 Emotionality, 115
 Enriched, 193
 Enriched environment, 167
 Environment, 193
 Environmental changes, 159
 Environmental enrichment, 209, 225, 233, 271, 279
 Episodic ataxia Type 2, 631
 Essential fatty acid, 545
 Estradiol, 729
 Estrogen, 729
 Ethanol, 45, 551, 631, 689, 787, 963
 Event-related potentials, 593
 Excitotoxicity, 287
 Exercise, 663
 Experimental antinociception, 863
 Exploration, 209
- Familial hemiplegic migraine, 631
 Fat, 545
 Fawn hooded rat, 185
 Fear and anxiety, 131
 Fear conditioning, 367, 391
 Fear expression, 367
 Fear-potentiated startle, 359
 Feeding, 529
 Female offspring, 105
 Fenfluramine, 639
 Fertility, 95
 Fetal alcohol syndrome, 45
 FFT, 467
 FK960, 511
 Flaxseed, 545
 Fluid balance, 475
 Fluoxetine, 703, 713
 Food intake, 545
 Formalin pain, 601
 Free radicals, 647
 Freezing, 7
 Frontal and occipital cortices, 557
 β-Funaltrexamine, 611
- Geller–Seifter, 359
 Gender, 729
 Genetically modified mice, 19
 Genetic background, 19
 Genotype, 821
Ginkgo biloba, 893
 Global ischemia, 439
 Glucocorticoid receptor, 95
 Glucocorticoid receptors, 105
 Glucose, 485
 Glutamate receptor, 287
 Glutamate receptors, 185
 Glutamate, 299, 317, 455, 467
 Group rearing, 7
- Habituation, 679
 Hallucinogenic drugs, 317
 Haloperidol, 505, 929
 Handling, 7
 Head trauma, 287
 Head twitches, 327
 Hippocampus, 233, 247, 689
 24 h maternal separation, 141
 Horizontal activity, 743
 HPA axis, 247
 HPRT, hypoxanthinephosphoribosyl transferase, 583
 5-HT₂ receptors, 327
 5-HT_{2A} receptor, 317
 5-HT_{2C}, 545
 Human, 447, 491, 729
 5-Hydroxytryptamine, 979
 5-Hydroxytryptamine_{2A} receptor, 317
 6-Hydroxydopamine, 455
 6-Hydroxydopamine, 697
 Hyperalgesia, 401, 573, 821
- Hyperosmotic, 475
 Hypothalamic–pituitary–adrenal axis, 53
 Hypothermia, 779
- Imipramine, 557, 941
 Impoverished, 193
 Inbred strains, 821
 Individual differences, 729
 Individuality, 679
 Infarct volume, 901
 Inflammation, 401
 Ingestive behavior, 545
 In situ hybridization, 185
 Interaction, 787
 Intranasal administration, 593
 Intravenous, 663
 IP, 439
 Iron deficiency, 813
 Isolation, 7, 689
 Isolation rearing, 177, 185
- 129/J mice, 655
- Kappa, 611
 Kinase, 299
 Kindling, 851
- Latent inhibition, 87
 Lateral hypothalamic area, 27
 LDH, 439
 Learning and memory, 307, 375, 565
 Learning, 193, 209, 233
 Learning processes, 723
 Levonorgestrel, 951
 Levonorgestrel metabolites, 951
 Limit, 901
 Linoleic acid, 545
 Linolenic acid, 545
 Locomotion, 77
 Locomotor activity, 333, 347, 551, 611, 655, 877, 883
 Locomotor sensitization, 551
 Long–Evans rats, 53
 Lorazepam, 703
 Lordosis, 53
 LPC, 593
 LTP, 299, 307, 375
 LY354740, 419
 LY354740 ((+)-2-aminobicyclo [3,1,0] hexane-2,6-dicarboxylic acid), 327
 LY367385, 439
 LY379268, 333, 339, 419, 455
 LY379268 ((–)-2-oxa-4-aminobicyclo [3,1,0] hexane-2,6-dicarboxylic acid), 327

- LY389795, 419
Lymphocyte, 797
- Macaca mulatta*, 271
Macrophage, 797
Male, 115
Male sexual behavior, 951
Marijuana, 835
Marmoset, 259
Maternal behavior, 61, 869
Maternal corticosterone, 105
Maternal deprivation, 177
Maternal retention, 869
Maternal separation, 77, 95, 115, 123, 131
Mechanical and cold hypersensitivity, 411
Mechanoreceptor, 475
Medial prefrontal cortex, 317
Melatonin, 805
Meloxicam, 521
Memory, 193, 209, 233, 391, 491, 511
Menstrual cycle phase, 729
Metabotropic glutamate receptor, 333, 339, 381, 401, 447, 455
Metabotropic glutamate receptors, 327, 347, 359, 367, 375, 411, 429, 439
Metabotropic glutamate receptors (mGluRs), 391
Metabotropic glutamate2/3 receptors, 317
Metabotropic, 299, 467
mGlu receptor, 339, 439
mGlu2 receptors, 317
mGlu2,3 receptors, 419
mGlu5, 359
mGluR, 411
mGluR5, 359, 375
Mice, 7, 327, 551, 883, 941
Microdialysis, 77
Milnacipran, 557
Modafinil, 723, 971
Monkeys, 61
Monoamine receptors, 247
Monoamines, 851
Morphine, 611, 697, 821, 883, 941
Morphine-3-glucuronide, 883
Morphine-6-glucuronide, 883
Morris maze, 45
Mother–infant interactions, 61
Motion sickness, 979
Motor activity, 339, 971
Motor coordination, 673
Motor neurons, 447
- Mouse model, 583
MPEP, 359, 375, 439
MS-377, 505
Mu, 611
Muscimol, 929
- N*-Acetylcysteine, 797
Naloxone, 611
Naltrindole, 611
NBM, 511
Nefazodone, 689
Neonatal, 95
Neonatal handling, 123, 233
Nerve growth factor, 167
Neural plasticity, 167, 233
Neurodegeneration, 843
Neurodevelopment, 19
Neuroendocrine, 475
Neuroleptics, 929
Neurological deficit, 901
Neuronal–glial interaction, 287
Neuronal networks, 307
Neuropathic pain, 411, 419
Neuropeptide Y, 147
Neuroprotection, 439, 455
Neurotrophin, 159
Neurotrophin-3, 167
NGF, 159
Nicotinamide, 901
Nicotine, 679
Nitriles, 647
NMDA, 185, 921, 439
Nociceptin/orphanin FQ, 123, 529
Nociception, 573, 863
Nonopioid, 521
Nootropic, 391
Nor-binaltorphimine, 611
Norepinephrine, 639
Nose–brain pathway, 593
Novelty, 209, 679
Novelty/sensation seeking, 225
Nucleus accumbens, 347
- OGD, 439
7-OH-DPAT, 753
Olanzapine, 769
Olfactory bulbectomized rat, 703
One-trial tolerance, 963
Open field, 703
Open-field, 115, 911
Open-field behaviour, 193
Operant behavior, 829
Operant response, 115
Osmoreceptor, 475
Oxidative stress, 565
Oxygen–glucose deprivation, 439
- P300, 593
Pacing, 53
Pain, 429, 521
Pain threshold, 601
Paracetamol, 521
Paraventricular nucleus, 147
Parkinsonism, 843
Parkinson's disease, 455
Paroxetine, 557
Paroxysmal dyskinesia, 631
Parturition, 869
Passive avoidance, 511
PD 152255, 753
Pentylentetrazol, 851, 921
Peripheral benzodiazepine receptor, 87
Persistent pain, 419
Pharmacokinetics, 883
Phencyclidine, 339
Phenethylamine hallucinogens, 317
Phenobarbital, 963
Phosphatase, 299
PI; propidium iodide, 439
Picrotoxin, 921
Pituitary–adrenal, 141
PNU-99194A, 753
Prenatal alcohol exposure, 45
Prenatal stress, 53
Prepulse inhibition, 177, 929
Prior test experience, 963
Progesterone, 729
Progesterin, 53
Propionic acid, 623
Propionic acidemia, 623
Protein malnutrition, 759
Puberty, 95
- Random effects models, 703
Rat, 115, 359, 375, 381, 391, 447, 565, 611, 663, 963
Rats, 61, 87, 209, 429, 557, 753, 759, 779, 787, 813, 851, 911
Receptivity, 53
 σ receptor, 505
REM, 467
REM sleep, 557
Reproduction, 95
Reserpine, 455
Responsiveness to change, 485
Restraint, 77
Review, 583
Reward, 115
Reward seeking, 225
RHA–RLA/Verh rats, 225
Rhesus monkeys, 829
Rostroventral medulla, 429
Rotational behaviour, 697

- S-14297, 753
Safflower, 545
Salicylate, 647
Salt arousal of drinking, 27
Schedule-induced drinking, 27
Schizophrenia, 159, 177, 929
Scopolamine, 829
SDAT, 511
Seizure susceptibility, 921
Seizures, 851
Selective breeding, 7
Self-administration, 663
Sensitization, 333, 339
Sensorimotor gating, 929
Serial probe recognition (SPR), 829
Serotonin, 317, 537, 545, 713
Sex, 663
Sex differences, 131, 485, 729
Sexual behavior, 95
Short-term memory, 829
SIB, self-injurious behavior, 583
Sigma receptors, 779
Sigma sites, 779
Single housing, 271
Sleep, 247, 467
Slow-wave sleep, 557
Social behavior, 7, 769
Social housing, 271
Social isolation, 209
Social reunion, 259
Social separation/novelty, 259
Social stress, 689
Somatostatin, 511
Spatial alternation, 375
Spatial learning, 381
Spatial navigation, 45
Specific pathogen-free, 271
Spectacled bear, 279
Spinal cord, 447
Spontaneous activity, 971
Spontaneous EPSP, 327
SR-141716, 911
Standardization, 209
Startle, 929
Stereotypic behavior, 583
Stimulants, 491, 729
Stimulus control, 759
Stress, 95, 123, 159, 177, 193, 209, 233, 537, 631, 703, 971
Stress hyporesponsive period, 141
Stress maternal deprivation, 45
Stress reactivity, 141
Stress response, 105
Stretch injury, 287
Subjective effects, 729
Substitution, 663
Sucrose preference, 115
Sultopride, 505
Suncus murinus, 979
Sympathetic nervous system, 247
Synaptic plasticity, 307, 375
Tacrine, 511
Tail flick latency, 601
Tail pinch, 537
Taste, 27
Taurine, 863
Testis, 95
 Δ^9 -THC, 911
Thermoregulation, 639, 779
Theta, 307
THIP, 759
Tilting plane, 673
Time course, 901
Tolerance, 821
Toluene, 921
Tottering mice, 631
Touch screen response, 829
TTX, 929
Two-way active avoidance, 87
Ultrasonic, 359
Ultrasonic vocalization, 131
Urinalysis, 247
Vaginocervical stimulation, 743
Vasopressin, 147
Ventral and dorsal hippocampus, 929
Vertical activity, 743
VMH, 601
Wakefulness, 557
Water maze, 623
Wheel-running, 663
Wheel-running activity, 805
WIN 55,212-2, 835
Zoo behavior, 279